CoChat

Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers

Open access
Salem, Mohamed E., El-Refai, Sherif M., Sha, Wei, Puccini, Alberto, Grothey, Axel, George, Thomas J., Hwang, Jimmy J., O'Neil, Bert, Barrett, Alexander S., Kadakia, Kunal C., Musselwhite, Laura W., Raghavan, Derek, Van Cutsem, Eric, Tabernero, Josep, Tie, Jeanne · 2022 · JCO Precision Oncology
Cited by 101

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

PURPOSE: Promising single-agent activity from sotorasib and adagrasib in KRAS G12C-mutant tumors has provided clinical evidence of effective KRAS signaling inhibition. However, comprehensive analysis of KRAS-variant prevalence, genomic alterations, and the relationship between KRAS and immuno-oncology biomarkers is lacking. MATERIALS AND METHODS: Retrospective analysis of deidentified records from 79,004 patients with various cancers who underwent next-generation sequencing was performed. Fisher's exact test evaluated the association between cancer subtypes and KRAS variants. Logistic regression assessed KRAS G12C comutations with other oncogenes and the association between KRAS variants and immuno-oncology biomarkers. RESULTS: Of the 79,004 samples assessed, 13,758 (17.4%) harbored KRAS mutations, with 1,632 (11.9%) harboring KRAS G12C and 12,126 (88.1%) harboring other KRAS variants ( KRAS non-G12C). Compared with KRAS non-G12C across all tumor subtypes, KRAS G12C was more prevalent in females (56% v 51%, false discovery rate-adjusted P value [FDR- P] = .0006), current or prior smokers (85% v 56%, FDR- P < .0001), and patients age > 60 years (73% v 63%, FDR- P ≤ .0001). The most frequent KRAS variants across all subtypes were G12D (29.5%), G12V (23.0%), G12C (11.9%), G13D (6.5%), and G12R (6.2%). KRAS G12C was most prevalent in patients with non–small-cell lung cancer (9%), appendiceal (3.9%), colorectal (3.2%), tumor of unknown origin (1.6%), small bowel (1.43%), and pancreatic (1.3%) cancers. Compared with KRAS non-G12C-mutated, KRAS G12C-mutated tumors were significantly associated with tumor mutational burden-high status (17.9% v 8.4%, odds ratio [OR] = 2.38; FDR- P < .0001). KRAS G12C-mutated tumors exhibited a distinct comutation profile from KRAS non-G12C-mutated tumors, including higher comutations of STK11 (20.59% v 5.95%, OR = 4.10; FDR- P < .01) and KEAP1 (15.38% v 4.61%, OR = 3.76; FDR- P < .01). CONCLUSION: This study presents the first large-scale, pan-cancer genomic characterization of KRAS G12C. The KRAS G12C mutation was more prevalent in females and older patients and appeared to be associated with smoking status. KRAS G12C tumors exhibited a distinct comutation profile and were associated with tumor mutational burden-high status.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/po.21.00245

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 101

Metadata

Authors
Salem, M. E., El-Refai, S. M., Sha, W., Puccini, A., Grothey, A., George, T. J., Hwang, J. J., O'Neil, B., Barrett, A. S., Kadakia, K. C., Musselwhite, L. W., Raghavan, D., Van Cutsem, E., Tabernero, J., & Tie, J.
Venue
JCO Precision Oncology
Published
2022-05
Volume
6
Issue
6
Pages
e2100245-e2100245
ISSN
2473-4284 (ISSN-L)
OpenAlex
W4220717021
Cited by
101
References
16
FWCI
7.36
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers. https://app.cochat.ai/papers/10.1200/po.21.00245
The paper
Salem, M. E., El-Refai, S. M., Sha, W., Puccini, A., Grothey, A., George, T. J., Hwang, J. J., O'Neil, B., Barrett, A. S., Kadakia, K. C., Musselwhite, L. W., Raghavan, D., Van Cutsem, E., Tabernero, J., & Tie, J. (2022). Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers. JCO Precision Oncology. https://doi.org/10.1200/po.21.00245

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.